Spyre Therapeutics said it is deprioritizing its rheumatoid arthritis antibody candidate after failing to meet its success bar in a Phase 2 study. The decision follows data described as modest in the interim, prompting the company to refocus resources. The TL1A-blocking approach had generated expectations for a new mechanism in RA management, but the Phase 2 outcome dampens near-term development prospects. Spyre’s move highlights how quickly mid-stage outcomes can reshape portfolios and force rapid reallocation across immunology pipelines.